KUALA LUMPUR, Nov 23 (Bernama) -- Adagene Inc (Adagene), a platform-driven, clinical-stage biopharmaceutical company, has announced two poster presentations featuring clinical data for its anti-CD137 agonist, ADG106, and anti-CTLA-4 monoclonal antibody, ADG116, at the European Society for Medical Oncology Immuno-Oncology Congress (ESMO-IO) 2021.
“These clinical data from two of our ongoing NEObody™ clinical programs showcase the importance of our pioneering approach to target a unique epitope and reflect the dynamic interactivity between an antibody and antigen,” said Co-founder, Chief Executive Officer and Chairman of Adagene, Peter Luo, Ph.D.
“The pharmacodynamic biomarker findings from our ongoing ADG106 trial with the anti-PD-1 toripalimab reinforce the potential synergistic combination for strong T-cell activation.
“For our novel anti-CTLA-4 program, data from the ongoing dose escalation of ADG116 monotherapy support the robust safety profile and dose dependent T-cell activation in both hot and cold tumors, suggesting potential clinical benefit following our translational studies.”
The conference abstracts are expected to be published on the ESMO-IO website on Dec 2, and posters available on Dec 6 in advance of the hybrid meeting being held virtually and in Geneva, Switzerland from Dec 8 to 11, according to a statement.
Both the ADG106 and ADG116 programs use Adagene’s innovative NEObody technology, which enables targeting of unique and highly conserved epitopes against a broad range of antigens.
These species cross-reactive antibodies not only have the potential to reveal new biological functions of the targets, but also facilitate preclinical studies using various immune intact animal models, resulting in high fidelity translation from preclinical to clinical studies.
The company is also developing an anti-CTLA-4 antibody, ADG126, using its SAFEbody® precision masking technology.
More details at https://investor.adagene.com.
-- BERNAMA
No comments:
Post a Comment